Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,131,091
  • Shares Outstanding, K 124,393
  • Annual Sales, $ 396,590 K
  • Annual Income, $ -528,630 K
  • EBIT $ -223 M
  • EBITDA $ -195 M
  • 60-Month Beta 0.94
  • Price/Sales 10.39
  • Price/Cash Flow N/A
  • Price/Book 17.39

Options Overview Details

View History
  • Implied Volatility 64.27% ( -1.61%)
  • Historical Volatility 60.56%
  • IV Percentile 30%
  • IV Rank 12.95%
  • IV High 125.43% on 12/27/23
  • IV Low 55.17% on 02/28/24
  • Put/Call Vol Ratio 0.53
  • Today's Volume 3,456
  • Volume Avg (30-Day) 1,919
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 76,293
  • Open Int (30-Day) 74,705

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.42
  • Number of Estimates 13
  • High Estimate -0.26
  • Low Estimate -0.67
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +42.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.62 +24.76%
on 11/21/24
35.72 -7.03%
on 12/09/24
+5.72 (+20.81%)
since 11/20/24
3-Month
24.34 +36.44%
on 11/05/24
35.72 -7.03%
on 12/09/24
+0.70 (+2.15%)
since 09/20/24
52-Week
24.34 +36.44%
on 11/05/24
73.80 -55.00%
on 01/09/24
-21.75 (-39.57%)
since 12/20/23

Most Recent Stories

More News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

APLS : 33.21 (+0.21%)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

APLS : 33.21 (+0.21%)
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

APLS : 33.21 (+0.21%)
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...

FOLD : 9.80 (+0.72%)
AVIR : 3.19 (+1.92%)
CRSP : 40.72 (+0.83%)
APLS : 33.21 (+0.21%)
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday

Sales of the company's top commercialized product didn't meet expectations.

$SPX : 5,930.85 (+1.09%)
APLS : 33.21 (+0.21%)
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

APLS : 33.21 (+0.21%)
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.

BAC : 44.17 (+1.82%)
ALPMY : 9.7900 (+1.45%)
APLS : 33.21 (+0.21%)
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

APLS : 33.21 (+0.21%)
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

APLS : 33.21 (+0.21%)
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

APLS : 33.21 (+0.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 35.40
2nd Resistance Point 34.84
1st Resistance Point 34.02
Last Price 33.21
1st Support Level 32.64
2nd Support Level 32.08
3rd Support Level 31.26

See More

52-Week High 73.80
Fibonacci 61.8% 54.91
Fibonacci 50% 49.07
Fibonacci 38.2% 43.23
Last Price 33.21
52-Week Low 24.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar